Vaccine maker BioNTech to use mRNA tech to target malaria

Monday, July 26, 2021 | Frank Jordans, Associated Press


In this May 6, 2021 file photo a man with a face mask leaves the headquarters of the German biotechnology company "BioNTech" in Mainz, Germany. (AP Photo/Michael Probst, file)

BERLIN (AP) — Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.

The Germany-based company, which developed the first widely approved coronavirus shot together with U.S. partner Pfizer, aims to begin clinical trials for a “safe and highly effective malaria vaccine” by the end of next year.

“We are already working on HIV and and tuberculosis, and malaria is the third big indication (disease) with a high unmet medical need,” BioNTech's chief executive, Ugur Sahin, told The Associated Press. “It has an incredible high number of people being infected every year, a high number of patients dying, a particularly severe disease and high mortality in small children.”

According to the World Health Organization, there were about 229 million cases of malaria worldwide in 2019. The global body estimates that 409,000 people died from malaria that year, with children under the age of 5 accounting for 67% of deaths.

Africa has by far the highest burden of the mosquito-borne disease worldwide, WHO says.

Sahin acknowledged that the effort is at a very early stage and there's no guarantee of success. But he said the company believes it’s “the perfect time to address this challenge” because of the insights it has gained from developing an mRNA vaccine against the coronavirus and a growing understanding of how malaria works.

Experts say developing a vaccine to prime the immune system against malaria will be tricky, however.

“The genome of Plasmodium, the parasite that causes malaria, is more complex than viruses,” said Prakash Srinivasan, an assistant professor at Johns Hopkins Bloomberg School of Public Health.

A malaria vaccine made by drugmaker GlaxoSmithKline already being trialed in three African countries has shown that inducing strong, long-lasting antibody levels is challenging, he said.

Existing and future variants of the parasite could also pose a challenge to developing an effective vaccine, said Srinivasan, whose lab is also working to develop a shot against malaria.

But Barton Haynes, director of the Duke Human Vaccine Institute, said the experience of the COVID-19 pandemic showed mRNA technology could be used to quickly adapt vaccines to work against new variants.

“The mRNA platform is going to be applicable to many different pathogens,” he said.

Sahin said early-stage development and testing of vaccines normally costs about $30-80 million.

The project, which is a collaboration with the World Health Organization, the European Commission and the Bill and Melinda Gates Foundation, "has no budget limits at the moment,” he added.

BioNTech said it is also seeking to establish an mRNA vaccine production facility in Africa, which is among the regions that have struggled to get sufficient supply of COVID-19 vaccine doses.

The company said it is working with partners to “evaluate how to establish sustainable mRNA manufacturing capabilities on the African continent to supply African countries with vaccines.” Once built, such a facility would be able to make various mRNA-based vaccines.

BioNTech and Pfizer have said they will deliver 1 billion doses of their COVID-19 vaccine to middle- and low-income countries this year, and another billion doses in 2022.

Last week, the two companies announced that a South African firm, the Biovac Institute, will become the first on the continent to start producing their coronavirus vaccine.

BioNTech has previously said it is working on a vaccine candidate for tuberculosis, with clinical trials aimed for 2022, and therapies for several forms of cancer.

Should you invest $1,000 in right now?

Before you consider , you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and wasn't on the list.

While currently has a "" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.7$44.19+0.5%3.53%18.97Hold$43.33
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.